This deregulation of IL-6 expression in prostate cancer cells is in fact mostly mediated by the constitutive NF-κB activation [61], and this activation occurs through signal transduction involving the upstream effectors NF-κB inducing kinase (NIK) and IKK. Here, NFKB1 is linked to prostate cancer.